Open an account

Silence Therapeutics

SLN · OTC

$19.61+$0.03 (+0.15%)TodayMarket closed ·
Prev close $19.58

About SLN

Silence Therapeutics PLC is a GB-based company operating in Biotechnology industry. Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The firm leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The firm focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.

Employees
88
Headquarters
London
Listed
Jan 5, 2010
Sector
Health Care
Industry
Biotechnology
Website
silence-therapeutics.com

SLN key statistics

Market cap
1.24B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
4.65M
Volume
13.96M
Open price
$19.57
High today
$19.65
Low today
$19.57
52 Week high
$19.61
52 Week low
$4.19

Silence Therapeutics (SLN) at a glance

Silence Therapeutics (SLN) last traded at $19.61, with a market cap of 1.24B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $19.57 and $19.65. The current price is 0.2% above the day's low and 0.2% below its high.

Volume so far is 13.96M shares, above the average of 4.65M shares a day.

Over the past year Silence Therapeutics has ranged from $4.19 to $19.61, and now sits 100% of the way up that range.

Silence Therapeutics met or beat analyst EPS estimates in 1 of the last 3 quarters. In Q2 FY26 it reported -$0.26 per share against an estimate of $0.00.

The average analyst price target is $39.35, 100.7% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 4 analystsAvg $39.35
Low
$25.11
Now
$19.61
High
$64.73

SLN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 3 quarters, by 0.0% on average.

  1. Q4 FY23: reported -$0.3674 per share against an estimate of $0.00
  2. Q4 FY24: reported $0.2131 per share against an estimate of $0.00
  3. Q2 FY26: reported -$0.26 per share against an estimate of $0.00

SLN news

  • Press releasePRNewswire

    Are BRZE, SLN, OPCH, RXO Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday

  • Shivdeep Dhaliwal

    Amazon.com, Cleveland-Cliffs, Disc Medicine, Silence Therapeutics and EyePoint: Why These 5 Stocks Are on Investors' Radars Today

  • Avi Kapoor

    Crude Oil Moves Higher; US Homebuilder Sentiment Falls In October

  • 12 Health Care Stocks Moving In Monday's Intraday Session

  • Vandana Singh

    Why Is Silence Therapeutics Stock Skyrocketing Monday?

  • Avi Kapoor

    Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday

  • Avi Kapoor

    Nasdaq Surges Over 1%; Fifth Third Bancorp Earnings Top Views

Similar companies

Companies in the same industry as Silence Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.